A preventable severe influenza A pneumonia after rituximab therapy for pemphigus vulgaris: a case report highlighting the critical role of vaccination
International Journal of Scientific Reports·
- DOI
- 10.18203/issn.2454-2156.intjscirep20262820
- PMID
- —
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Medip Academy
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The case draws attention to influenza infection as a reported complication in a patient receiving rituximab who had declined vaccination. Its relevance is limited to illustrating an individual clinical event and does not establish population-level risk or vaccine effectiveness.
Structured evidence summary
Research question
The report examines severe influenza A pneumonia occurring after rituximab treatment in a patient with pemphigus vulgaris who had not received influenza vaccination.
Study design
This is a single-patient case report describing clinical presentation, laboratory findings, imaging, treatment, and recovery.
Population and setting
The subject was a 38-year-old man with pemphigus vulgaris who developed influenza A H3 pneumonia 20 days after a second rituximab infusion. The abstract describes hospital-based evaluation and treatment, including oxygen supplementation, but does not specify a country or institution.
Main findings
Respiratory testing identified influenza A H3, and imaging showed bilateral basal infiltrates with ground-glass changes. The patient was hospitalized and treated with oseltamivir, antibiotics, and supplemental oxygen, then recovered without intensive care admission.
Public-health relevance
The case draws attention to influenza infection as a reported complication in a patient receiving rituximab who had declined vaccination. Its relevance is limited to illustrating an individual clinical event and does not establish population-level risk or vaccine effectiveness.
Important limitations
The single-case design cannot estimate frequency, comparative risk, or causality, and the abstract does not provide a comparator or systematic follow-up. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable under influenza, vaccination, and treatment classifications and may provide context for literature review involving influenza in the setting of rituximab therapy. It is an individual case report and should not be interpreted as confirmation of a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.